CD28-negative CD4 + and CD8 + T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies

Journal of Infectious Diseases

Volumn 205, Issue 11, 2012, Pages 1730-1738

  Tassiopoulos, Katherine ^a   Landay, Alan ^b   Collier, Ann C ^c   Connick, Elizabeth ^d   Deeks, Steven G ^e   Hunt, Peter ^e   Lewis, Dorothy E ^f   Wilson, Cara ^d   Bosch, Ronald ^g  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^g CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD28 ANTIGEN; VIRUS RNA;

ADULT; AGE; AGING; ANTIRETROVIRAL THERAPY; ARTICLE; CD28- CD4+ T LYMPHOCYTE; CD28- CD8+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CELL AGING; CELL EXPANSION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG THERAPY; ETHNICITY; FEMALE; GENDER; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIGENS, CD28; ANTIGENS, CD4; ANTIGENS, CD8; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HUMANS; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84861083813     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis260     Document Type: Article

References (28)

1. Effros R, Fletcher C, Gebo K, et al. Workshop on HIV infection and aging: what is known and future directions. Clin Infect Dis 2008; 47:542-53.
2. Lenschow D, Walunas T, Bluestone J. CD28/B7 system of T-cell costimulation. Annu Rev Immunol 1996; 14:233-58.
3. Effros RB, Allsopp R, Chiu CP, et al. Shortened telomeres in the expanded CD28?CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 1996; 10:F17-22. (Pubitemid 26229506)
4. Cao W, Jamieson B, Hultin L, Hultin P, Effros R, Detels R. Premature aging of T-cells is associated with faster HIV-1 disease progression. J Acquir Immune Defic Syndr 2009; 50:137-47.
5. Hunt P, Sinclair E, Epling L, et al. T-cell senescence and proliferation defects persist in treated HIV-infected individuals maintaining viral suppression and are associated with poor CD4+ T-cell recovery. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco, California. Abstract 316.
6. Valdez H, Connick E, Smith K, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16:1859-66.
7. Lange C, Lederman M, Madero J, et al. Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. J Acquir Immune Defic Syndr 2002; 30:33-40. (Pubitemid 34506685)
8. Desai S, Ronquillo R, Usuga X, et al. Immune senescence, activation, and abnormal T-cell homeostasis despite effective HAART, a hallmark of early aging in HIV disease. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Canada. Abstract 381.
9. Kaplan R, Sinclair E, Landay AL, et al. T-cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011; 203:452-63.
10. Smurzynski M, Collier AC, Koletar S, et al. AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT): rationale, design, and baseline characteristics. HIV Clin Trials 2008; 9:268-81.
11. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-303. (Pubitemid 37509737)
12. Malhotra U, Bosch RJ, Chan E, et al. Association of T-cell proliferative responses and phenotype with virus control in chronic progressive HIV-1 disease. J Infect Dis 2004; 189:515-9. (Pubitemid 38210589)
13. Landay AL, Spritzler J, Kessler H, et al. Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor-or protease inhibitorcontaining antiretroviral regimen. J Infect Dis 2003; 188:1444-54. (Pubitemid 37523929)
14. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-61. (Pubitemid 38917251)
15. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-106. (Pubitemid 351679596)
16. Kalayjian R, Landay A, Pollar R, et al. Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. J Infect Dis 2003; 187:1924-33. (Pubitemid 36724491)
17. Volberding P, Demeter L, Bosch R, et al. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS 2009; 23:1987-95.
18. Robbins GK, Spritzler J, Chan E, et al. Incomplete reconstitution of T-cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group Protocol 384. Clin Infect Dis 2009; 48:350-61.
19. Lin J, Epel E, Cheon J, et al. Analyses and comparisons of telomerase activity and telomere length in human T and B cells: insights for epidemiology of telomere maintenance. J Immunol Methods 2010; 352:71-80.
20. Vivar N, Ruffin N, Sammicheli S, Hejdeman B, Rethi B, Chiodi F. Survival and proliferation of CD28? T-cells during HIV-1 infection relate to the amplitude of viral replication. J Infect Dis 2011; 203:1658-67.
21. Fish E. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol 2008; 8:737-44.
22. Meier A, Chang J, Chan E, et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med 2009; 15:955-9.
23. Kovacs A, Al-Harthi L, Christensen S, Mack W, Cohen M, Landay A. CD8+ T-cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis 2008; 197:1402-7. (Pubitemid 351706464)
24. Paravisini A, Cianchetta MS, Garcia R, et al. Pattern of CD28 expression on CD8+ T-cells in a group of coinfected and monoinfected HIV and HCV patients. J Allergy Clin Immunol 2007; 119: S180.
25. Giubilato S, Liuzzo G, Brugaletta S, et al. Expansion of CD4+CD28null T-lymphocytes in diabetic patients: exploring new pathogenetic mechanisms of increased cardiovascular risk in diabetes mellitus. Eur Heart J 2011; 32:1214-26.
26. Jonasson L, Tompa A, Wikby A. Expansion of peripheral CD8+ T cells in patients with coronary artery disease: relation to cytomegalovirus infection. J Intern Med 2003; 254:472-8. (Pubitemid 37346631)
27. Betjes M, Huisman M, Weimar W, Litjens N. Expansion of cytolytic CD4+CD28? T cells in end-stage renal disease. Kidney Int 2008; 74:760-7.
28. Giorgi JV, Majchrowicz MA, Johnson TD, Hultin P, Matud J, Detels R. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS 1998; 12:1833-44. (Pubitemid 28454449)